BMJ neurology open · 2026
Evaluation of cortical pathology in primary-progressive multiple sclerosis: a post hoc analysis of the SPRINT-MS trial.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Krijnen Eva A, Bruijn Anne M, Eloyan Ani, Schoonheim Menno M, Fox Robert J, Klawiter Eric C
Аннотация
BACKGROUND: Multiple sclerosis (MS) involves cortical injury, including cortical lesion (CL) development. Ibudilast treatment was found to slow progression of whole brain and cortical atrophy, but the effect of ibudilast on CLs is unknown. The present study aims to evaluate the treatment effect of ibudilast on CL development and whether the effect of ibudilast on brain atrophy is modified by CLs in primary-progressive MS (PPMS).
METHODS: In this longitudinal study, we analysed data of 102 people with PPMS (ibudilast: n=49; placebo: n=53) from the Secondary and Primary Progressive Ibudilast NeuroNEXT Trial in Multiple Sclerosis. CLs were identified on artificial intelligence-generated double inversion-recovery images created from T1 and T2 images at 3T MRI and rated at baseline and week 96. Atrophy was measured by cortical thickness and brain parenchymal fraction.
RESULTS: CLs were detected in all participants with PPMS with a median count of 22 (11-34) in the ibudilast group and 28 (13-44) in the placebo group. At baseline, treatment groups did not differ in any brain volume measure or CL count. Higher CL counts at baseline were associated with higher CL formation during follow-up (B(95% CI)=0.20 (0.12 to 0.29), p<0.001), independent of ibudilast treatment.Change in CL count did not differ between treatment groups (mean difference (SD)=0.07 (0.29), p=0.364). Protective effect of ibudilast on cortical thickness was more prominent in subjects with greater CL formation, but this relationship was not observed with whole brain atrophy.
CONCLUSIONS: Ibudilast treatment does not affect CL development in PPMS. Its protective effect on cortical thinning is more prominent with greater CL formation.
TRIAL REGISTRATION NUMBER: NCT01982942.
METHODS: In this longitudinal study, we analysed data of 102 people with PPMS (ibudilast: n=49; placebo: n=53) from the Secondary and Primary Progressive Ibudilast NeuroNEXT Trial in Multiple Sclerosis. CLs were identified on artificial intelligence-generated double inversion-recovery images created from T1 and T2 images at 3T MRI and rated at baseline and week 96. Atrophy was measured by cortical thickness and brain parenchymal fraction.
RESULTS: CLs were detected in all participants with PPMS with a median count of 22 (11-34) in the ibudilast group and 28 (13-44) in the placebo group. At baseline, treatment groups did not differ in any brain volume measure or CL count. Higher CL counts at baseline were associated with higher CL formation during follow-up (B(95% CI)=0.20 (0.12 to 0.29), p<0.001), independent of ibudilast treatment.Change in CL count did not differ between treatment groups (mean difference (SD)=0.07 (0.29), p=0.364). Protective effect of ibudilast on cortical thickness was more prominent in subjects with greater CL formation, but this relationship was not observed with whole brain atrophy.
CONCLUSIONS: Ibudilast treatment does not affect CL development in PPMS. Its protective effect on cortical thinning is more prominent with greater CL formation.
TRIAL REGISTRATION NUMBER: NCT01982942.